when your lung cancer has spread to nearby tissues (locally advanced) and is unable to be removed (unresectable) by surgery and has responded or stabilized following chemotherapy and radiation treatment as your first treatment when your lung cancer has spread to other parts of the body (metastatic...
Targeted therapies are not chemotherapy or immunotherapy.3 Is Tagrisso (osimertinib) an immunotherapy? No, Tagrisso is not an immunotherapy, but a targeted therapy. Targeted therapies work differently than traditional chemotherapy. Immunotherapy stimulates the immune system to help the body fight cancer....
1L, first-line; 2L, second-line; CRT, chemoradiotherapy; CT (pem/plat), pemetrexed plus platinum-based chemotherapy; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; T790M...
When TAGRISSO is administered in combination with pemetrexed and platinum-based chemotherapy, modify the dose of any one of the treatments for the management of adverse reactions, as appropriate. For TAGRISSO dose modification instructions, see Table 2. Withhold, reduce the dose or permanently disconti...
The most common side effects of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy include: low white blood cell counts low platelet counts rash diarrhea mouth sores changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from the nailbed...
1L, first-line; 2L, second-line; CRT, chemoradiotherapy; CT (pem/plat), pemetrexed plus platinum-based chemotherapy; EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor mutation; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; T790M...
2024年02月16日-(特拉华州威尔明顿)-阿斯利康的TAGRISSO® (osimertinib)奥西替尼 联合化疗已在美国获得批准,用于治疗患有局部晚期或转移性表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC)的成年患者。 美国食品和药物管理局 (FDA)优先审查 后的批准基于《新英格兰医学杂志》上发表的 FLAURA2 III 期试验的结果。
阿斯利康近日宣布,其表皮生长因子受体(EGFR)酪氨酸激酶抑制剂Tagrisso(osimertinib,奥希替尼)与化疗联合,用于治疗局部晚期或转移性EGFR突变(EGFRm)非小细胞肺癌(NSCLC)成人患者的补充新药申请(sNDA)已获美国FDA的批准。 Tagrisso是第三代、不可逆的EGFR-TKI,已在临床证实对NSCLC具有疗效。该药物在美国、欧盟、中国和日本...
AstraZeneca’s researchers stated that when patients are diagnosed with early-stage lung cancer and receive standard treatment – surgery followed by adjuvant chemotherapy in appropriate patients – disease recurrence within five years of surgery is high. In fact, relapse occurs in 45% of Stage IB,...
Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a human anti-HER3 antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker. It is designed to target and deliver chemotherapy inside cancer cells that express HER3 as a cell surface ...